Search

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

Jun 13 2014 Posted in Press releases

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Meetings Sponsor Program

The European Hematology Association (EHA) is a membership organization serving clinicians and researchers with an active interest in hematology in Europe and beyond. We bring together relevant stakeholders to promote excellence in patient care through education, research, and advocacy.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Sanquin Blood Supply will culture erythrocytes for transfusion purposes

Oct 01 2013 Posted in Press releases

ABO-Rh-D matched transfusions result in alloimmunisation in 3-5% of recipients. Once allo-immunized, it may become very difficult to find appropriate donor erythrocytes, especially when multiple antibodies or rare combinations of antibodies are present.

EHA attends the EuNet-INNOCHRON Final Conference

Apr 16 2024

The EuNet-INNOCHRON Final Conference, a significant event in the field of hematology, took place in Chania, Crete, Greece from April 4-6, 2024.